Patents by Inventor LAIMONIS KAVALIERIS

LAIMONIS KAVALIERIS has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods for detection of markers bladder cancer and inflammatory conditions of the bladder and treatment thereof
    Patent number: 11208698
    Abstract: Embodiments of this invention include methods for detection of markers of bladder cancer and inflammatory conditions of the bladder. Particularly, methods include detection of expression of certain genetic markers for bladder cancer and markers for detection of inflammatory conditions of the bladder. These methods provide improved detection of the markers, and provide better detection of bladder cancer and inflammatory conditions of the bladder.
    Type: Grant
    Filed: May 24, 2018
    Date of Patent: December 28, 2021
    Assignee: PACIFICEDGE LIMITED
    Inventors: Parry John Guilford, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan
  • Methods for Treating Urothelial Carcinoma Using Genotypic and Phenotypic Biomarkers
    Publication number: 20190203300
    Abstract: New methods for treating patents for urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up or treatment is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients having or are at risk for developing UC.
    Type: Application
    Filed: November 19, 2018
    Publication date: July 4, 2019
    Applicant: Pacific Edge Limited
    Inventors: David Darling, James Miller Suttie, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan, Satish Kumar
  • Methods for detecting genetic and phenotypic biomarkers of urothelial carcinoma and treatment thereof
    Patent number: 10131955
    Abstract: New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: November 20, 2018
    Assignee: PACIFIC EDGE LIMITED
    Inventors: David Darling, James Miller Suttie, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan, Satish Kumar
  • Methods for Detection of Markers Bladder Cancer and Inflammatory Conditions of the Bladder
    Publication number: 20180298452
    Abstract: Embodiments of this invention include methods for detection of markers of bladder cancer and inflammatory conditions of the bladder. Particularly, methods include detection of expression of certain genetic markers for bladder cancer and markers for detection of inflammatory conditions of the bladder. These methods provide improved detection of the markers, and provide better detection of bladder cancer and inflammatory conditions of the bladder.
    Type: Application
    Filed: May 24, 2018
    Publication date: October 18, 2018
    Applicant: Pacific Edge Limited
    Inventors: Parry John Guilford, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan
  • Polymerase chain reaction test kits for detecting markers of bladder cancer
    Patent number: 9982305
    Abstract: This invention relates to the use of human neutrophil marker interleukin 8 receptor B (IL8Rb) for detection of bladder cancer, and more particularly to the use of EL8Rb for discriminating between transitional cell carcinoma of the bladder (TCC) and inflammatory conditions of the bladder.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: May 29, 2018
    Assignee: PACIFIC EDGE LIMITED
    Inventors: Parry John Guilford, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan
  • Triaging of Patients Having Asymptomatic Hematuria Using Genotypic and Phenotypic Biomarkers
    Publication number: 20170275697
    Abstract: New methods for identifying patents with hematuria who are at low risk of having urothelial cancer (UC) include combining selected phenotypic variables with levels of genotypic expression into a new metric, the “G+P INDEX.” The G+P INDEX combines age, sex, smoking history, presence of hematuria, and frequency of hematuria with genotypic expression of the genetic markers, MDK, CDC2, HOXA13, IGFBP5, and optionally IL8Rb, then determining of the G+P INDEX value obtained for a patient is within one of three groups, either: (1) at High Risk of UC, (2) at Risk of UC, or (3) at Low Risk of UC. For groups 1 and 2, further clinical and laboratory work up is indicated, and patients in group 3 are monitored periodically to determine the need for further clinical workup. Using the G+P INDEX can save substantial time, effort, and funds by avoiding unnecessary medical diagnostic procedures for patients at Low Risk of UC.
    Type: Application
    Filed: May 19, 2016
    Publication date: September 28, 2017
    Applicant: Pacific Edge Limited
    Inventors: David Darling, James Miller Suttie, Mark Dalphin, Laimonis Kavalieris, Paul O'Sullivan, Satish Kumar
  • NOVEL MARKER FOR DETECTION OF BLADDER CANCER AND/OR INFLAMMATORY CONDITIONS OF THE BLADDER
    Publication number: 20170002420
    Abstract: This invention relates to the use of human neutrophil marker interleukin 8 receptor B (IL8Rb) for detection of bladder cancer, and more particularly to the use of EL8Rb for discriminating between transitional cell carcinoma of the bladder (TCC) and inflammatory conditions of the bladder.
    Type: Application
    Filed: November 11, 2011
    Publication date: January 5, 2017
    Applicant: PACIFIC EDGE LIMITED
    Inventors: PARRY JOHN GUILFORD, MARK DALPHIN, LAIMONIS KAVALIERIS, PAUL O'SULLIVAN